Randomized trial · people
Tirzepatide: HbA1c fell 2.1% vs 1.1% with insulin lispro in SURPASS-6
Checked against the paper Randomized trialPublished by PepVault
The takeaway
For people with type 2 diabetes already on basal insulin, this trial found adding tirzepatide lowered HbA1c and weight more than mealtime insulin, with fewer low blood sugar events, while gut symptoms were its most common side effect.
- Kind
- Randomized trial
- Studied in
- People
- Number studied
- 1428
- Published
- 2023
- Journal
- JAMA
What they tested
The team tested whether weekly tirzepatide works at least as well as mealtime insulin lispro when added to insulin glargine in people with type 2 diabetes whose blood sugar was not controlled on basal insulin.
How the study was done
An open-label, randomized phase 3b trial of 1428 adults with type 2 diabetes who were already using basal insulin, run at 135 sites across 15 countries. On top of insulin glargine, each person got weekly tirzepatide shots (5 mg, 10 mg or 15 mg arms) or insulin lispro 3 times a day for 52 weeks.

Model. Individual results vary.
What they found
At week 52, HbA1c (a 3-month average of blood sugar) changed by -2.1% with tirzepatide (all doses pooled) and -1.1% with insulin lispro, reaching 6.7% vs 7.7%, an estimated difference of -0.98%; tirzepatide was both noninferior and superior. Body weight changed by -9.0 kg with tirzepatide and 3.2 kg with insulin lispro. An HbA1c under 7.0% was reached by 68% on tirzepatide and 36% on insulin lispro. Low blood sugar events (under 54 mg/dL or severe) ran at 0.4 per patient-year with tirzepatide and 4.4 with insulin lispro, while the most common tirzepatide side effects were mild to moderate gut symptoms such as nausea in 14%-26%.
What it doesn’t show
The trial was open-label, so participants and staff knew which treatment was given. It lasted 52 weeks and only included adults already on basal insulin, compared against mealtime insulin rather than placebo.
The paper
Rosenstock et al. Tirzepatide vs Insulin Lispro Added to Basal Insulin in Type 2 Diabetes: The SURPASS-6 Randomized Clinical Trial. JAMA. 2023.
The compound
More studies on Tirzepatide
- Tirzepatide plus apitegromab: 1.9 kg less lean mass loss in EMBRAZERandomized trial · people · 2026
- Dulaglutide: switching to tirzepatide beat dose escalation on HbA1cRandomized trial · people · 2025
- Tirzepatide: up to 19.7% weight loss at 176 weeks in SURMOUNT-1Randomized trial · people · 2025
- Tirzepatide: about 75% of weight lost was fat in SURMOUNT-1Randomized trial · people · 2025
- Tirzepatide: most reached a weight plateau by week 72 in SURMOUNT-1Randomized trial · people · 2025
- Tirzepatide: 20.2% weight loss vs 13.7% on semaglutide at 72 weeksRandomized trial · people · 2025
- Every study on Tirzepatide
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.